story of the week
Pertuzumab, Trastuzumab, and Docetaxel for HER2-Positive Metastatic Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Pertuzumab, Trastuzumab, and Docetaxel for HER2-Positive Metastatic Breast Cancer (CLEOPATRA): End-of-Study Results From a Double-Blind, Randomised, Placebo-Controlled, Phase 3 Study
Lancet Oncol 2020 Mar 12;[EPub Ahead of Print], SM Swain, D Miles, SB Kim, YH Im, SA Im, V Semiglazov, E Ciruelos, A Schneeweiss, S Loi, E Monturus, E Clark, A Knott, E Restuccia, MC Benyunes, J CortésFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.